MaxWell Biosystems develops high-density microelectrode array platforms designed for recording and stimulation of neural cells in vitro. The company’s systems enable precise interaction with neuronal networks cultured in laboratory environments. Its technology supports detailed investigation of neural activity at scale, combining hardware and software optimized for high-throughput experimentation. MaxWell Biosystems positions its platform within neuroscience research and drug discovery contexts.

The technology uses dense arrays of microelectrodes to capture electrical activity from large populations of neurons simultaneously. These electrodes also enable targeted electrical stimulation, allowing researchers to probe network dynamics and responses to interventions. Integrated software tools support real-time data acquisition, visualization, and analysis across thousands of channels. This setup enables controlled, repeatable experiments on neural cultures with high temporal and spatial resolution.

MaxWell Biosystems targets applications in basic neuroscience research, neuropharmacology, and preclinical drug screening. The platform is used by academic and industry researchers studying neural function, disease models, and treatment effects in vitro. Its focus reflects growing demand for scalable, high-resolution tools that accelerate understanding of neural systems and therapeutic discovery.